Cardiology Headline News

Hyperinsulinemia and/or insulin resistance biomarkers, such as fasting, plasma insulin and proinsulin, predicted aortic stenosis, independent of other cardiovascular risk factors, according to study results published in Annals of Medicine.

CHICAGO — Zerlasiran, a novel injectable small interfering RNA molecule, lowered lipoprotein(a) by more than 80% compared with placebo at 36 weeks, according to the results of the ALPACAR trial.

GLP-1 receptor agonists improved clinical outcomes related to kidney and heart health while lowering mortality rates for individuals with diabetes, chronic kidney disease or preexisting cardiovascular disease with overweight or obesity.

CHICAGO — Results from a new survey highlight a gap between patients’ information needs about sexual health and the actual support provided by health care professionals.

Women with hypertensive disorders of pregnancy history were more likely to experience coronary artery disease years earlier and have a greater risk for myocardial infarction with both obstructive and nonobstructive coronary arteries.

Breast arterial calcification seen on routine mammograms, especially among younger women, is associated with increased risk for death and adverse cardiovascular outcomes, including heart failure, myocardial infarction and stroke, data show.

Adults with pulmonary arterial hypertension functional class three or four faced a decreased risk for all-cause mortality or morbidity events with Winrevair vs. placebo, according to phase 3 ZENITH trial topline results.

People with type 2 diabetes had twice the number of CVD events vs. matched counterparts, with events starting 3 decades before diagnosis, suggesting their elevated CVD risk may be attributable to factors tied to diabetes development.

BridgeBio Pharma announced that acoramidis, its small molecule stabilizer of transthyretin, has been approved by the FDA for the reduction of CV death and hospitalization in patients with transthyretin amyloid cardiomyopathy.

Physicians generally use life insurance to achieve certain wealth planning goals — from protecting the family against the risk of a breadwinner’s early death to providing an estate for heirs and more.